Armata Pharmaceuticals’ (ARMP) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $7.00 target price on the stock.

Armata Pharmaceuticals Stock Up 1.5 %

Shares of Armata Pharmaceuticals stock opened at $1.98 on Thursday. The firm has a market cap of $71.64 million, a PE ratio of -1.21 and a beta of 0.78. Armata Pharmaceuticals has a 1 year low of $1.89 and a 1 year high of $4.48.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.